COVID-19 vaccination often triggers a constellation of transitory inflammatory symptoms including gout. Therefore, a clinical delivery population-based observational and cross-sectional study was conducted to analyse the risk of gout flares in the first 3 months after COVID-19 vaccination with inactivated virus, and whether colchicine would reduce gout flares following post-COVID-19 vaccination.
The study included 549 participants, with a median age of 39 years. Four hundred and sixty-two (84.2%) received the COVID-19 vaccine, in which 400 (86.6%) had received two doses. It was observed that 43.9% developed at least one gout flare in the 3 months after any vaccine. Most of these flares were reported within one month after the first or second dose of the vaccine. COVID-19 vaccine was associated with sixfold higher odds of gout. Specifically, patients who received the Sinovac Life vaccine got significantly higher odds of a gout flare. However, colchicine prophylaxis was associated with a 47% less likelihood of having an increase in gout flare burden after the vaccination.
The findings of this clinical delivery population-based cross-sectional study provide important implications for COVID-19 vaccine administration in people with gout. The overall data indicate a higher odds of gout flare within 3 months after the COVID-19 vaccine and that colchicine prophylaxis is associated with markedly reduced odds of a postvaccine gout flare. Furthermore, the prevalence of gout flares after the administration of other vaccines needs to be investigated.
Join Thousands of Doctors who Trust WhiteCoats as their Professional Success Partner
For more queries, Call +91-7406-485-000 or mail us at email@example.com
Download our App